



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

APS6-45

Cat. No.:	HY-124944		
CAS No.:	2188236-41-9		
Molecular Formula:	C ₂₃ H ₁₆ F ₈ N ₄ O ₃		
Molecular Weight:	548.39		
Target:	Ras		
Pathway:	GPCR/G Protein		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 250 mg/mL (455.88 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		1.8235 mL	9.1176 mL	18.2352 mL
		5 mM		0.3647 mL	1.8235 mL	3.6470 mL
	10 mM		0.1824 mL	0.9118 mL	1.8235 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (3.79 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	APS6-45 is an orally active tumor-calibrated inhibitor (TCI). APS6-45 inhibits RAS/MAPK signaling and exhibits antitumor activity ^[1] .
In Vitro	APS6-45 (3-30 nM; 3 weeks) strongly suppresses TT human Medullary Thyroid Carcinoma (MTC) cells colony formation in a soft agar assay ^[1] . APS6-45 (1 μM; 1 h) strongly inhibits RAS pathway activity signaling in human MTC cell lines TT and MZ-CRC-1 ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	APS6-45 (10 mg/kg; p.o. daily for 30 d) inhibits growth of TT tumors in mice and does not affect body weight ^[1] . APS6-45 (0.1-160 mg/kg; a single p.o.) does not cause detectable toxic effects in mice ^[1] . APS6-45 (20 mg/kg; a single p.o.) exhibits long half-life (5.6 h), C _{max} (9.7 μM) and AUC ₀₋₂₄ (123.7 μM•h) in mice ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female nude mice (6 weeks) are implanted with TT cells ^[1]
Dosage:	10 mg/kg
Administration:	P.o. daily for 30 days
Result:	Led to partial or complete responses in 75% and was well tolerated.
Animal Model:	Male ICR mice (6 weeks of age) ^[1]
Dosage:	20 mg/kg (Pharmacokinetic Analysis)
Administration:	A single p.o.
Result:	$T_{1/2}$ =5.6 h, C_{max} =9.7 μ M, AUC_{0-24} =123.7 μ M•h.

REFERENCES

[1]. Sonoshita M, et, al. A whole-animal platform to advance a clinical kinase inhibitor into new disease space. Nat Chem Biol. 2018 Mar;14(3):291-298.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA